© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Immunotherapy
JAVELIN Bladder 100 Trial Impresses, Ensures Patients Have Access to Second-Line Immunotherapy at Disease Progression
July 07, 2020
Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.
Fecal Microbiota Transplant May Emerge as a Treatment Strategy in Melanoma Following Immunotherapy Failure
June 27, 2020
In patients with advanced melanoma whose disease progressed on immunotherapy, the use of fecal microbiota transplant achieved objective responses, in a phase I study.
Combination Immunotherapy Appears Promising in Breast Cancer Subtypes
June 25, 2020
Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.
iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell Responses in Advanced Solid Tumors
June 22, 2020
“RO7198457 in combination with atezolizumab induced immune responses in the majority of patients, including preliminary data demonstrating the detection of neoantigen-specific T-cell responses within the tumor."
Survival Advantage Associated With Immune-Related Toxicity Reveals Racial Disparities in Solid Tumors
June 12, 2020
The study showed that the development of immune-related adverse events in advanced solid tumors was positively correlated with improved progression-free survival and overall survival in a retrospective analysis, which also showed that Caucasian patients developed immune-related adverse events more frequently than African American patients.
Questioning When to Start Immunotherapy for Patients With Oncogenic Drivers
May 21, 2020
Karen Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
BMI May Stratify Clinical Trials to Measure Survival With Immunotherapy in NSCLC
May 18, 2020
A study found correlation between body mass index in patients with non–small cell lung cancer treated with atezolizumab and improved survival outcomes.
Exploring Biomarkers for Immunotherapy Treatment in Lung Cancer
May 13, 2020
Jamie E. Chaft, MD, discusses biomarkers used to identify patients with lung cancer who would benefit from immunotherapy and the possibility for future biomarkers in this setting.
Doctors Debate: Should Immunotherapy Be Given Before or After Surgical Resection in Locally Advanced NSCLC?
April 22, 2020
“We don’t have a good understanding of why some patients have a robust response to immunotherapy and others do not. That’s important, not only in terms of selecting patients but also in terms of the therapy approach. This is one reason why clinical trials are incredibly important.”
Discussing the Evolution of Immunotherapy in Lymphomas
April 21, 2020
Joshua Brody, MD, discusses how he sees the use of immunotherapy evolving in coming years.